AstraZeneca agreed with Accent Therapeutics to jointly develop the treatment of cancer

AstraZeneca announced a collaboration with Accent Therapeutics for research, development and commercialization of innovative medicines that have an impact on RNA-modifying proteins in the treatment of cancer.

The cooperation of companies focused on targeted therapies aimed at RNA-modifying proteins that control various aspects of the biology of RNA. This is a new approach to fixing the processes that can lead to cancer or drug resistance.

Under the agreement, Accent Therapeutics will be responsible for research and development in the framework of pre-clinical studies and completion of clinical trials of phase I. After the end of the first stage of AstraZeneca will lead the development and commercialization of this program, and Accent Therapeutics will have the opportunity to develop and commercialize jointly with AstraZeneca in the United States. AstraZeneca will also receive an exclusive option to license worldwide rights to two additional programs in preclinical studies for which Accent Therapeutics will perform a series of pre-clinical activities.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]